Publications

Publication: Journal of Neurology

Gao J, Jones J, Damato EM, Coles A. 

20 March 2019

Publication: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

Carolin Koriath, Tammaryn Lashley, William Taylor, Ronald Druyeh, Athanasios Dimitriadis, Nicola Denning, Julie Williams, Jason D. Warren, Nick C. Fox, Jonathan M. Schott, James B. Rowe, John Collinge, Jonathan D. Rohrer, Simon Mead

19 March 2019

Apolipoprotein E (ApoE) is the most important genetic risk factor for Alzheimer’s disease (AD), with ApoE4 thought to enhance and accelerate amyloid‐β (Aβ) pathology. ApoE4 has recently been described to increase neurodegeneration in a mouse model of frontotemporal dementia (FTD), in vitro, and in patients, demonstrating that ApoE4 modifies tauopathy independently of Aβ. This raises the question whether ApoE genotype also modifies the clinical phenotype in patients with FTD with tau pathology.

The ApoE4 genotype lowered age at onset in patients with FTD and tau pathology, particularly once accounting for confounding effects of Aβ pathology.

The researchers conclude that ApoE4 accelerates neurodegeneration in FTD patients with MAPT mutations or FTLD‐tau pathology, independent of Aβ.

Publication: Journal of the American College of Cardiology Volume 73, Issue 10, 19 March 2019, Pages 1107-1119

Cartlidge TRG, Doris MK, Sellers SL, Pawade TA, White AC, Pessotto R, Kwiecinski J, Fletcher A, Alcaide C, Lucatelli .

19 March 2019

Publication: J Proteome Res

Harshfield EL, Koulman A, Ziemek D, Marney L, Fauman EB, Paul DS, et al.

19 March 2019

Publication: European Radiology.

Zaccagna F, Riemer F, Priest AN, McLean MA, Allinson K, Grist JT, et al.

19 March 2019

Publication: European Radiology

Caglic I, Brzan PP, Warren A, Bratt O, Shah N, Barrett T.

18 March 2019

Publication: Lancet

Januszewicz W, Corrie P, Liu H, Chan J, Fitzgerald RC, di Pietro M.

16 March 2019

Publication: The New England Journal of Medicine

Ference BA, Ray KK, Catapano AL, Ference TB, Burgess S, Neff DR, et al.

14 March 2019

Publication: Journal of Neurology Neurosurgery and Psychiatry

Edwin Jabbari, John Woodside, Tong Guo, Nadia K Magdalinou, Viorica Chelban, Dilan Athauda, Andrew J Lees, Thomas Foltynie, Henry Houlden, Alistair Church, Michele TM Hu, James B Rowe, Henrik Zetterberg, Huw R Morris

13 March 2019

The high degree of clinical overlap between atypical parkinsonian syndromes (APS) and Parkinson’s disease (PD) makes diagnosis challenging. The researchers aimed to identify novel diagnostic protein biomarkers of APS using multiplex proximity extension assay (PEA) testing.

The biological processes regulated by the significant proteins include cell differentiation and immune cell migration. Delta and notch-like epidermal growth factor-related receptor (DNER) had the strongest effect size in APS versus controls and APS versus PD analyses. DNER is highly expressed in substantia nigra and is an activator of the NOTCH1 pathway which has been implicated in the aetiology of other neurodegenerative disorders including Alzheimer’s disease.

PEA testing has identified potential novel diagnostic biomarkers of APS.

Publication: Nature

Rueda OM, Sammut SJ, Seoane JA, Chin SF, Caswell-Jin JL, Callari M, et al.

13 March 2019

Publication: Clinical and Translational Oncology

Sushentsev N, Martin H, Rimmer Y, Barrett T.

13 March 2019

Publication: Immunity

Tomas Castro-Dopico, Thomas W. Dennison, John R. Ferdinand, Rebeccah J. Mathews, Aaron Fleming, Dean Clift, Benjamin J. Stewart, Chenzhi Jing, Konstantina Strongili, Larisa I. Labzin, Edward J.M. Monk, Kourosh Saeb-Parsy, Clare E. Bryant, Simon Clare, Miles Parkes, Menna R. Clatworthy

12 March 2019

______________________________________________________________________

Summary:

Inflammatory bowel disease (IBD) is due to aberrant responses of the gut mucosa to the resident microbiome. The identification of which immune cells are involved in IBD will lead to identification of novel therapeutic targets.

Publication: Immunity

Tomas Castro-Dopico, Thomas W. Dennison, John R. Ferdinand, Simon Clare, Miles Parkes, Menna R. Clatworthy et al

12 March 2019

Summary: 

Inflammatory bowel disease (IBD) is due to aberrant responses of the gut mucosa to the resident microbiome.

This research looked at Crohn’s and Ulcerative Colitis (both types of IBD) to identify which immune cells are involved in IBD, and to help identify novel therapeutic targets.

Publication: European Heart Journal

Chiesa ST, Charakida M, McLoughlin E, Nguyen HC, Georgiopoulos G, Motran L, Elia Y, Marcovecchio ML, Dunger DB, Dalton RN, Daneman D, Sochett E, Mahmud FH, Deanfield JE.

12 March 2019

Publication: Neurology

Tay J, Tuladhar AM, Hollocks MJ, Brookes RL, Tozer DJ, Barrick TR, et al.

12 March 2019

Publication: Journal of Magnetic Reson Imaging

Riemer F, McHugh D, Zaccagna F, Lewis D, McLean MA, Graves MJ, et al.

12 March 2019

Publication: Expert Review of Neurotherapeutics

Killen MJ, Giorgi-Coll S, Helmy A, Hutchinson PJ, Carpenter KL.

8 March 2019

Publication: Intensive Care Medicine

French CE, Delon I, Dolling H, Sanchis-Juan A, Shamardina O, Mégy K, Abbs S, Austin T, Bowdin S, Branco RG, Firth H, , Rowitch DH, Raymond FL

07 March 2019

Publication: Clinical Infectious Diseases

Dyson ZA, Klemm EJ, Palmer S, Dougan G.

7 March 2019

Publication: BMJ

Luo S, Au Yeung SL, Zhao JV, Burgess S, Schooling CM.

6 March 2019